Evidence map›Paper›PMID 40569890›Full record

ArticleJournal of the International AIDS Society2025

Modelling the impact of initiation delay, duration and prior PrEP on the efficacy of post-exposure prophylaxis containing a tenofovir/emtricitabine backbone.

Lanxin Zhang, Simon Collins, Julie Fox, Max von Kleist

Abstract read
In one paragraph

Article in Journal of the International AIDS Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025
    Guideline
  2. Canadian guideline on HIV pre- and postexposure prophylaxis: 2025 update.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025
    Guideline
  3. Article
  4. Review
  5. Article
  6. Article
  7. HIV Post Exposure Prophylaxis: prospects, opportunities and challenges.Journal of the International AIDS Society · 2025
    Article
  8. Preventing HIV in women in Africa.Nature medicine · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lanxin ZhangProject group 5 "Systems Medicine of Infectious Disease", Robert-Koch Institute, Nordufer 20, Berlin, 13353, Germany.ORCID https://orcid.org/0000-0002-3740-4450
Simon CollinsHIV i-Base, London, UK.
Julie FoxDepartment of Infectious Disease, King's College London, London, UK.
Max von KleistProject group 5 "Systems Medicine of Infectious Disease", Robert-Koch Institute, Nordufer 20, Berlin, 13353, Germany.ORCID https://orcid.org/0000-0001-6587-6394

Funding

Bundesministerium für Bildung und Forschung 01KI2016Deutsche For schungsgeme in schaft (DFG) under Germany's Excellence Strategy-The Berlin Mathematics Research Center MATH+ (EXC-2046/1, project ID 390685689)Robert Koch Institut, Sonder for schungsmittel (SoFo)
6 · The paper itself

Abstract

introductionPre- and post-exposure prophylaxis (PrEP and PEP) are important pillars of the HIV prevention portfolio to reduce the risk of acquisition just before or after HIV exposure. While PrEP efficacy has been elucidated in many randomized clinical trials, corresponding data for PEP is extremely difficult to obtain in a controlled setting. Consequently, it is almost impossible to study the impact of PEP initiation delay and duration on HIV risk reduction clinically, which would inform recommendations on PEP use.

methodsWe employ pharmacokinetics, pharmacodynamics and viral dynamics models, along with individual factors, such as drug adherence to investigate the impact of initiation delay and PEP duration on HIV risk reduction. We evaluated PEP using two- and three-drug regimens with a TDF/FTC backbone. Moreover, we study PEP efficacy in the context of PrEP-to-PEP transitions.

resultsIn our simulations, early initiation of PEP emerged as a pivotal factor for HIV risk reduction. We found that 2-drug (TDF/FTC) PEP may insufficiently protect when initiated > 1 hour post-exposure. When adding a third drug, early initiation was still a critical factor; however, over 90% efficacy could be achieved when PEP was initiated 48 hours post-exposure and taken for at least 14-28 days, depending on the efficacy of the third-drug component. When investigating PrEP-PEP transitions, we observed that preceding PrEP can (1) contribute directly to prophylactic efficacy, and (2) boost subsequent PEP efficacy by delaying initial viral dynamics and building-up drug concentrations, overall facilitating self-managed transitioning between PrEP and PEP.

conclusionsOur study confirms the critical role of early (< 48 hours) PEP initiation, preferably with three drugs taken for 28 days. Self-start with TDF/FTC and later addition of a third drug is better than not self-starting. Furthermore, our study highlights the synergy between recent PrEP intake and PEP and may help to inform recommendations on PEP use.

Indexed as

Anti-HIV AgentsChemopreventionEmtricitabineHIV InfectionsPost-Exposure ProphylaxisPre-Exposure ProphylaxisTenofovirHumansMaleTime FactorsTreatment OutcomeAnti-HIV AgentsEmtricitabineTenofovirHIVmathematical modellingpost‐exposure prophylaxispre‐exposure prophylaxisquantitative systems pharmacologyTDF/FTC

Identifiers

PMID40569890
PMCPMC12231637

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.